<DOC>
	<DOCNO>NCT02482454</DOCNO>
	<brief_summary>The purpose study determine whether combine radiofrequency ablation ( RFA ) cytokine-induced killer cell ( CIK ) transfusion prolong survival patient cholangiocarcinoma .</brief_summary>
	<brief_title>Radiofrquency Ablation Combined With Cytokine-induced Killer Cells Patients With Cholangiocarcinoma</brief_title>
	<detailed_description>The primary objective evaluate whether RFA follow CIK transfusion prolong survival patient cholangiocarcinoma .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<criteria>Patients histologically confirm cholangiocarcinoma Primary lesion ( cholangiocarcinoma ) resect Serum bilirubin level 2.0 mg/dl less . Performance status 0 1 . Expected survival 1 year . Informed consent patient . With extrahepatic metastasis With neoplastic disease measurable treated cholangiocarcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>radiofrequency ablation</keyword>
	<keyword>cytokine-induced killer cell</keyword>
	<keyword>cholangiocarcinoma</keyword>
</DOC>